Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy is a research paper published in Proceedings of the National Academy of Sciences (2020). On theSindex it has a DataRank of 3.9. It has been cited 208 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.801
From this paper's citation signal
Citation Network Contribution
3.1
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Grant: T32-DK007737
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Grant: P30 DK034987
HHS | NIH | National Cancer Institute
Grant: CA207416
HHS | NIH | National Cancer Institute
Grant: CA098468
U.S. Department of Agriculture
Grant: 055336
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Grant: P40 OD010995